Company: SPRB
Filing Date: 2025-04-15
Form Type: 8-K
Source: 0000950170-25-053944
Chunk: 0

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-04-15
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition.

On April 15, 2025, Spruce Biosciences, Inc. (the “ Company”) issued a press release providing a corporate update that included updates on its new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B, anticipated upcoming milestones, and its cash and cash equivalents balance of $38.8 million as of December 31, 2024 (the “ Press Release”). The full text of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“ Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (“ Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.